This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
5 Stocks With Recent Price Strength to Gain From July Rally
by Nalak Das
Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are IMCR, FC, ASC, SNEX and ARLP.
Wall Street Analysts Think Immunocore Holdings PLC Sponsored ADR (IMCR) Could Surge 29%: Read This Before Placing a Bet
by Zacks Equity Research
The consensus price target hints at a 29.4% upside potential for Immunocore Holdings PLC Sponsored ADR (IMCR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Has McKesson (MCK) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how McKesson (MCK) and Immunocore Holdings PLC Sponsored ADR (IMCR) have performed compared to their sector so far this year.
Best Momentum Stocks to Buy for July 12th
by Zacks Equity Research
CCBG, IMCR and FSTX made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 12, 2022.
Vertex (VRTX) to Buy ViaCyte to Speed Up VX-880 Program
by Zacks Equity Research
Vertex (VRTX) will acquire ViaCyte for $320 million in cash.
Here's Why "Trend" Investors Would Love Betting on Immunocore Holdings PLC Sponsored ADR (IMCR)
by Zacks Equity Research
If you are looking for stocks that are well positioned to maintain their recent uptrend, Immunocore Holdings PLC Sponsored ADR (IMCR) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Here's Why Immunocore Holdings PLC Sponsored ADR (IMCR) is a Great Momentum Stock to Buy
by Zacks Equity Research
Does Immunocore Holdings PLC Sponsored ADR (IMCR) have what it takes to be a top stock pick for momentum investors? Let's find out.
Wall Street Analysts See a 36% Upside in Immunocore Holdings PLC Sponsored ADR (IMCR): Can the Stock Really Move This High?
by Zacks Equity Research
The consensus price target hints at a 35.9% upside potential for Immunocore Holdings PLC Sponsored ADR (IMCR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Are Medical Stocks Lagging Galapagos (GLPG) This Year?
by Zacks Equity Research
Here is how Galapagos NV (GLPG) and Immunocore Holdings PLC Sponsored ADR (IMCR) have performed compared to their sector so far this year.
Zacks.com featured highlights include Immunocore Holdings, United Fire Group, FTI Consulting, Consolidated Water and Huron Consulting
by Zacks Equity Research
Immunocore Holdings, United Fire Group, FTI Consulting, Consolidated Water and Huron Consulting are part of zacks Screen of the week article.
Here's What Could Help Immunocore Holdings PLC Sponsored ADR (IMCR) Maintain Its Recent Price Strength
by Zacks Equity Research
Immunocore Holdings PLC Sponsored ADR (IMCR) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
5 Stocks With Recent Price Strength to Maximize Your Gains
by Nalak Das
Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are IMCR, UFCS, CWCO, HURN and FCN.
Seattle Genetics (SGEN) Moves 12.7% Higher: Will This Strength Last?
by Zacks Equity Research
Seattle Genetics (SGEN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Zacks Industry Outlook Highlights Alkermes, Geron, Immunocore and BELLUS Health
by Zacks Equity Research
Alkermes, Geron, Immunocore and BELLUS Health have been highlighted in this Industry Outlook article.
4 Biotech Stocks With Bright Prospects to Buy Amid Recovery
by Zacks Equity Research
New drug approvals and development of treatments for COVID-19 should maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and pipeline progress position ALKS, GERN, IMCR and BLU well amid the volatility.
Wall Street Analysts See an 80% Upside in Immunocore Holdings PLC Sponsored ADR (IMCR): Can the Stock Really Move This High?
by Zacks Equity Research
The mean of analysts' price targets for Immunocore Holdings PLC Sponsored ADR (IMCR) points to an 80.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Immunocore (IMCR) Up on Deal With Sanofi for Skin Cancer Study
by Zacks Equity Research
Immunocore (IMCR) signs a collaboration agreement with Sanofi to study the combination of Kimmtrak with the latter's SAR444245 for treating metastatic cutaneous melanoma. Shares up.
Walgreens Boots (WBA) Q2 Earnings Top Estimates, Margins Up
by Zacks Equity Research
Strong execution across business segments, led by COVID-19 vaccinations and testing, drove Walgreens' (WBA) fiscal second-quarter top line.
Immunocore Holdings PLC Sponsored ADR (IMCR) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Immunocore Holdings PLC Sponsored ADR (IMCR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Wall Street Analysts See a 135% Upside in Immunocore Holdings PLC Sponsored ADR (IMCR): Can the Stock Really Move This High?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 134.8% in Immunocore Holdings PLC Sponsored ADR (IMCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.